文献速递中医内科中药与中成药合理使用中医康复

脉络宁口服液抑制AMPK/mTOR相关凋亡并促进CREB/BDNF神经保护改善恢复期脑缺血

Mailuoning oral liquid attenuates convalescent cerebral ischemia by inhibiting AMPK/mTOR-associated apoptosis and promoting CREB/BDNF-mediated neuroprotection.
PubMed 文献 · J Ethnopharmacol · 2023-06-03

本研究探讨脉络宁口服液(MLN O)在缺血性卒中恢复期的神经保护与凋亡关系。采用MCAO/R大鼠模型和OGD/R PC-12细胞模型,发现MLN O减少脑梗死体积和神经功能缺损评分,抑制炎症细胞浸润和神经元凋亡,促进胶质增生和神经元存活。机制上MLN O抑制AMPK/mTOR活性、激活CREB/BDNF通路,从而抑制线粒体相关凋亡。

要点

  • MLN O减轻MCAO大鼠脑梗死体积和神经功能缺损。
  • MLN O抑制神经元凋亡并促进CREB/BDNF神经保护通路。
  • MLN O通过抑制AMPK/mTOR影响线粒体相关凋亡。

核心结论

  • MLN O在缺血性卒中恢复期通过抑制AMPK/mTOR影响线粒体相关凋亡,并促进CREB/BDNF介导的神经保护。

研究设计与样本

  • 体内采用大脑中动脉闭塞/再灌注(MCAO/R)大鼠模型,体外采用氧糖剥夺/复氧(OGD/R)PC-12细胞模型。

主要发现

  • MLN O明显减少MCAO大鼠脑梗死体积和神经功能缺损评分。
  • MLN O抑制炎症细胞浸润和神经元凋亡,促进胶质增生、神经元存活和神经保护。
  • MLN O降低血浆和缺血脑皮质中LDH和细胞色素c含量,增加c-AMP表达,促进脑皮质BDNF表达。
  • MLN O改善OGD/R后PC-12细胞活力、恢复细胞形态、减轻细胞损伤并抑制神经元凋亡。
  • MLN O抑制促凋亡蛋白Bax、细胞色素c、Cleaved caspase 3和HIF-1α表达,促进Bcl-2表达,并抑制AMPK/mTOR活性、激活CREB/BDNF通路。

临床怎么用

  • 在缺血性卒中恢复期可考虑使用脉络宁口服液,其机制涉及抑制凋亡和促进神经保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Ischemic stroke is divided into acute, subacute and convalescent phases according to the time of onset. Clinically, Mailuoning oral liquid (MLN O) is a traditional Chinese patent medicine for treating ischemic stroke. Previous studies have shown that MLN O could prevent acute cerebral ischemia-reperfusion. However, its underlying mechanism remains unclear. AIM OF THE STUDY: To investigate the relationship between neuroprotection and apoptosis for clarifying MLN O mechanism in the recovery phase of ischemic stroke. MATERIALS AND METHODS: We imitated stroke using middle cerebral artery occlusion/reperfusion (MCAO/R) in vivo and oxygen-glucose deprivation/reoxygenation (OGD/R) in vitro models. The infarct volume, neurological deficit scores, HE staining, Nissl staining, TUNEL staining, immunohistochemistry, and Western blot were correspondingly performed to find pathological changes and detect neuronal apoptosis in rat cerebral cortex. The contents of LDH, Cyt-c, c-AMP and BDNF in rat plasma and cerebral cortex were detected by ELISA. Cell viability was measured by CCK8 assay. Cell morphology, Hoechst 33342 staining and Annexin-V-Alexa Fluor 647/PI staining were performed to assess neuronal apoptosis. The expression levels of proteins were evaluated by western blotting. RESULTS: MLN O obviously reduced brain infarct volume and neurological deficit scores in MCAO rats. MLN O inhibited inflammatory cell infiltration and neuronal apoptosis, but promoted gliosis, neuronal survival, and neuroprotection in the cortical region of MCAO rats. Additionally, MLN O decreased the amount of LDH and cytochrome c, while increasing the expression of c-AMP in the plasma and ischemic cerebral cortex of MCAO rats, and promoting the expression of BDNF in the cortical tissue of MCAO rats. Besides, MLN O improved cell viability, restored cell morphology, while attenuating cell damage, inhibiting neuronal apoptosis following OGD/R in PC-12 cells. Moreover, MLN O inhibited apoptosis by suppressing the expression of pro-apoptotic-associated proteins, including Bax, cytochrome c, Cleaved caspase 3 and HIF-1α, whereas accelerating the expression of Bcl-2 in vivo and in vitro. Furthermore, MLN O inhibited the activity of AMP-activated protein kinase (AMPK)/mechanistic target of rapamycin (mTOR), but activated the signaling pathway of cAMP-response element binding protein (CREB)/brain-derived neurotrophic factor (BDNF) in MCAO rats and OGD/R-stimulated PC-12 cells. CONCLUSIONS: These results demonstrated that MLN O inhibited AMPK/mTOR to affect apoptosis associated with mitochondria, leading to improve CREB/BDNF-mediated neuroprotection in the recovery period of ischemic stroke in vivo and in vitro.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Liu X, Fan L, Li J, et al. Mailuoning oral liquid attenuates convalescent cerebral ischemia by inhibiting AMPK/mTOR-associated apoptosis and promoting CREB/BDNF-mediated neuroprotection. J Ethnopharmacol. 2023. PMID: 37277084. doi:10.1016/j.jep.2023.116731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。